Novo Ventures company plans to fetch USD 127.5m on the US stock exchange

The newly founded spinout company Vectivbio, which Novo Ventures has invested millions of kroner in, has announced that it is getting listed in the US with the goal of fetching USD 127.5m for developing a treatment for short bowel syndrome, which Zealand Pharma is also banking on.

Novo Ventures Senior Partner Naveed Siddiqi | Photo: Novo Ventures / PR

The battle for the short bowel syndrome market is getting tougher.

The Novo Ventures-backed spinout company Vectivbio will soon enter the US stock exchange hoping to land USD 127.5m for further developing the firm's drug hope apraglutide. Following solid results in a phase II study for short bowel syndrome, drug was recently tested on the first patient in the crucial phase III trial, according to a press announcement from the Swiss company, which was founded in 2020 with backing from a series of life science venture funds.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs